10.1371/journal.pone.0163447
Lanfang Li
Lanfang
Li
Qingya Luo
Qingya
Luo
Zhe Xie
Zhe
Xie
Guiqin Li
Guiqin
Li
Chengyi Mao
Chengyi
Mao
Yi Liu
Yi
Liu
Xin Wen
Xin
Wen
Na Yin
Na
Yin
Jianzhong Cao
Jianzhong
Cao
Jing Wang
Jing
Wang
Li Li
Li
Li
Jianhua Yu
Jianhua
Yu
Fang Wang
Fang
Wang
Ping Yi
Ping
Yi
Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer
Public Library of Science
2016
IHC
PCR
eukaryotic translation initiation factor 4 gamma
survival time
eIF 4G expression
eIF 4G protein levels
RNA Binding Protein eIF 4G
Serous Ovarian Cancer Background Ovarian cancer
cancer tissues
eIF 4G protein expression
eIF 4G
surface epithelial cell specimens
RBP
tumor stage
2016-09-26 17:40:26
Dataset
https://plos.figshare.com/articles/dataset/Characterization_of_the_Expression_of_the_RNA_Binding_Protein_eIF4G1_and_Its_Clinicopathological_Correlation_with_Serous_Ovarian_Cancer/3862317
<div><p>Background</p><p>Ovarian cancer is the most lethal type of malignant tumor in gynecological cancers and is associated with a high percentage of late diagnosis and chemotherapy resistance. Thus, it is urgent to identify a tumor marker or a molecular target that allows early detection and effective treatment. RNA-binding proteins (RBPs) are crucial in various cellular processes at the post-transcriptional level. The eukaryotic translation initiation factor 4 gamma, 1(eIF4G1), an RNA-binding protein, facilitates the recruitment of mRNA to the ribosome, which is a rate-limiting step during the initiation phase of protein synthesis. However, little is known regarding the characteristics of eIF4G1 expression and its clinical significance in ovarian cancer. Therefore, we propose to investigate the expression and clinicopathological significance of eIF4G1 in ovarian cancer patients.</p><p>Methods</p><p>We performed Real-time PCR in 40 fresh serous ovarian cancer tissues and 27 normal ovarian surface epithelial cell specimens to assess eIF4G1mRNA expression. Immunohistochemistry (IHC) was used to examine the expression of eIF4G1 at the protein level in 134 patients with serous ovarian cancer and 18 normal ovarian tissues. Statistical analysis was conducted to determine the correlation of the eIF4G1 protein levels with the clinicopathological characteristics and prognosis in ovarian cancer.</p><p>Results</p><p>The expression of eIF4G1 was upregulated in serous ovarian cancer tissues at both the mRNA (P = 0.0375) and the protein (P = 0.0007) levels. The eIF4G1 expression was significantly correlated with the clinical tumor stage (P = 0.0004) and omentum metastasis (P = 0.024). Moreover, patients with low eIF4G1 protein expression had a longer overall survival time (P = 0.026).</p><p>Conclusions</p><p>These data revealed that eIF4G1 is markedly expressed in serous ovarian cancer and that upregulation of the eIF4G1 protein expression is significantly associated with an advanced tumor stage. Besides, the patients with lower expression of eIF4G1 tend to have a longer overall survival time. Thus, eIF4G1 may contribute to the occurrence and metastasis of ovarian cancer and can serve as a potential therapeutic target for the treatment of ovarian cancer.</p></div>